

Technology Advisory Committee A Interests Register

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [Review of TA540] [ID5084]

Publication Date: 01/05/2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
Dr Patrick De Barr	Committee A Member	Direct – financial interests	Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication.	25/01/2024	It was agreed that Patrick's declaration would not prevent him from being part of the committee.
Beth Phillips	Clinical Expert	Indirect – Financial	Takeda (brentuximab vedotin) Speakers fees: ASH highlights meeting (educational meeting, no direct relation to specific products); 16/1/2023; £1676.50 Travel/conference registration: ISHL and virtual ASH	13/02/2024	It was agreed that Beth's declaration would not prevent her from providing expert comments to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>attendance: 22/10/22 – 13/12/22; amount not known</p> <p>Research funding via the University of Manchester for RADAR clinical trial (as co-investigator, CI: Prof John Radford): 10/2020 – ongoing; £3,860,091</p>		